|NASDAQ: GMVD||Healthcare / Medical Devices & Instruments / -|
|0.9100||-0.7500||-45.18%||Vol 14.20M||1Y Perf -96.27%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||0.03 2.97%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||+ 37.52|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||-1.28||Earnings Rating||—|
|Market Cap||1.79M||Earnings Date||27th Apr 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||989.12K|
|Avg. Monthly Volume||262.24K|
|Avg. Quarterly Volume||896.91K|
G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) stock closed at 0.91 per share at the end of the most recent trading day (a -45.18% change compared to the prior day closing price) with a volume of 14.20M shares and market capitalization of 1.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 111 people. G Medical Innovations Holdings Ltd. CEO is Yacov Geva.
The one-year performance of G Medical Innovations Holdings Ltd. stock is -96.27%, while year-to-date (YTD) performance is -72.26%. GMVD stock has a five-year performance of %. Its 52-week range is between 1.62 and 57.05, which gives GMVD stock a 52-week price range ratio of -1.28%
G Medical Innovations Holdings Ltd. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 5.08, a price-to-sale (PS) ratio of 1.98, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -182.11%, a ROC of -67.65% and a ROE of 3 843.72%. The company’s profit margin is -%, its EBITDA margin is -324.70%, and its revenue ttm is $2.22 Million , which makes it $2.22 revenue per share.
Of the last four earnings reports from G Medical Innovations Holdings Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. G Medical Innovations Holdings Ltd.’s next earnings report date is 27th Apr 2023.
The consensus rating of Wall Street analysts for G Medical Innovations Holdings Ltd. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for G Medical Innovations Holdings Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
G Medical Innovations Holdings Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
G Medical Innovations Holdings Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 63.64, ATR14 : 0.56, CCI20 : -183.43, Chaikin Money Flow : -0.72, MACD : -0.27, Money Flow Index : 27.61, ROC : -51.08, RSI : 32.54, STOCH (14,3) : 0.89, STOCH RSI : 0.01, UO : 25.34, Williams %R : -99.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of G Medical Innovations Holdings Ltd. in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.
CEO: Yacov Geva
Telephone: +972 89584777
Address: 5 Oppenheimer Street, Rehovot 7670105, WA, IL
Number of employees: 111
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.